Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced positive results from a Phase I
clinical trial highlighting targeted multi-functional immunotherapeutic
responses induced by the Company's DPX-0907 vaccine in a poster presentation at
the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Data indicated that 61 percent (11/18) of the study's evaluable cancer patients,
and more specifically in 89% (8/9) of evaluable study patients with breast or
ovarian cancer, experienced the desired targeted T cell responses against one or
more of the seven key cancer-specific antigens contained in DPX-0907. 


T cells are sophisticated white blood cells that play a critical role in the
body's fight against cancer. They can recognize cancer cells with high
specificity and actively infiltrate tumors. Importantly, T cells can have
immunological memory with the potential to provide durable anti-cancer
responses. Immunotherapies aim to activate these T cells with the intent to
induce durable clinical responses in cancer patients. 


The presented findings demonstrated that the antigen specific T cells triggered
by DPX-0907 treatment often secreted multiple type 1 cytokines, suggesting the T
cells possess the multifunctional activity that is believed to be important in
controlling cancer. As previously reported, the study met the primary objective
of safety with overall results demonstrating that DPX-0907 is generally well
tolerated by all patients and is considered safe at both dose levels with no
vaccine related serious adverse effects reported. 


DPX-0907, a targeted therapeutic vaccine designed to train the immune system to
recognize and attack cancer cells, combines seven tumor associated antigens
(TAAs) with Immunovaccine's novel DepoVax(TM) adjuvanting delivery platform. T
cells that have been trained to recognize the antigens are expected to
specifically target cancer cells, leaving normal healthy cells unharmed.
DPX-0907 leverages the DepoVax platform to create a depot effect upon
vaccination that presents the antigens and adjuvant to the immune system for a
prolonged period of time.


Immunovaccine's poster presentation (abstract #2588) included additional
encouraging data on the trial's observed immune responses in advanced stage
ovarian, breast and prostate cancer patients. Study results indicated that
DPX-0907 possesses favorable immune induction potential as 73 percent of immune
responders generated a response following the first vaccination. Further, in 83
percent of responders, the responses were detected at greater than or equal to
two time points following vaccination and 64 percent maintained a persistent
response at one month following a third vaccination.


The open-label, dose-escalating Phase I trial was conducted at five centers in
the U.S., with patients receiving three injections (0.25 mL or 1 mL doses) of
the active immune therapy DPX-0907 three weeks apart. Safety was assessed in
eleven patients in the 0.25 mL dose group and eleven patients in the 1 mL dose
group. The immunogenicity results were based on an analysis of nine evaluable
patients in the 0.25 mL dose group and nine evaluable patients in the 1 mL dose
group.


"The ability to train the immune system to generate specific multi-functional T
cells is a key milestone for the DPX-0907 clinical program," said Marc Mansour,
Ph.D., Immunovaccine's chief science officer. "Also encouraging is the fact that
these results were achieved across multiple cancer types, suggesting broad
potential applications for this targeted immunotherapeutic."


About Immunovaccine 

Immunovaccine Inc. applies its novel vaccine delivery platform to the
development of vaccines for cancer therapy and infectious diseases. The
company's DepoVax(TM) platform is a patented lipid delivery system that presents
antigens plus adjuvant to the immune system for a prolonged period and has the
potential to enhance immune responses. Immunovaccine has advanced its platform
technology and proprietary cancer vaccine into Phase I human clinical trials and
has demonstrated both safety and immunogenicity potential. The Company is also
capitalizing on the broad potential of its delivery platform by creating new
DepoVax-based vaccines through multiple development collaborations. In addition
to the Company's human health vaccine strategy, it continues to capture value
from animal health vaccine applications. Immunovaccine has several key
partnerships in the animal health sector including an agreement with Pfizer
Animal Health, which has licensed the Company's delivery technology platform to
develop vaccines for livestock. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release.